Jump to content
Join us at the SGCM Arcade Drive and win up to $27,000 discounts from Volkswagen and ŠKODA! Read more... ×
steveluv

Sinovac showed efficacy of 50.4%

Recommended Posts

Twincharged

The Pfizer vaccine showed efficacy of 95%
The Moderna vaccine was 94.1%
Sinovac is 50.4%, dafug!


https://asia.nikkei.com/Spotlight/Coronavirus/Sinovac-vaccine-disappoints-at-50.4-efficacy-latest-Brazil-data

Sinovac vaccine disappoints at 50.4% efficacy: latest Brazil data
Results come as scientists slam biomed center for raising 'unrealistic' hopes

https%3A%2F%2Fs3-ap-northeast-1.amazonaw
The Butantan biomedical production center in Sao Paulo, Brazil, is being blasted by scientists and observers for releasing partial data only days ago that generated unrealistic expectations.    © Reuters
January 13, 2021 10:34 JST

SAO PAULO (Reuters) -- A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week.

The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunization during the second wave of the world's second-deadliest COVID-19 outbreak.

Several scientists and observers blasted the Butantan biomedical center for releasing partial data just days ago that generated unrealistic expectations. The confusion may add to skepticism in Brazil about the Chinese vaccine, which President Jair Bolsonaro has criticized, questioning its "origins."

"We have a good vaccine. Not the best vaccine in the world. Not the ideal vaccine," said microbiologist Natalia Pasternak, criticizing Butantan's triumphant tone.

Last week, the Brazilian researchers had celebrated results showing 78% efficacy against "mild-to-severe" COVID-19 cases, a rate they later described as "clinical efficacy."

They said nothing at the time about another group of "very mild" infections among those who received the vaccine that did not require clinical assistance.

Ricardo Palacios, medical director for clinical research at Butantan, said on Tuesday that the new lower efficacy finding included data on those "very mild" cases.

"We need better communicators," said Gonzalo Vecina Neto, a professor of public health at the University of Sao Paulo and former head of Brazilian health regulator Anvisa.

Piecemeal disclosures about Chinese vaccine trials globally have raised concerns that they are not subject to the same public scrutiny as U.S. and European alternatives.

Palacios and officials in the Sao Paulo state government, which funds Butantan, emphasized the good news that none of the volunteers inoculated with CoronaVac had to be hospitalized with COVID-19 symptoms.

Public health experts said that alone will be a relief for Brazilian hospitals that are buckling under the strain of surging case loads. However, it will take longer to curb the pandemic with a vaccine that allows so many mild cases.

"It's a vaccine that will start the process of overcoming the pandemic," Pasternak said.

Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac.

In the meantime, Turkish researchers said last month that CoronaVac was 91.25% effective based on an interim analysis. Indonesia gave the vaccine emergency use approval on Monday based on interim data showing it is 65% effective.

Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines.

Still, COVID-19 vaccines in use from Pfizer Inc with partner BioNTech SE and Moderna Inc proved to be about 95% effective in preventing illness in their pivotal late-state trials.

The disappointing CoronaVac data is the latest setback for vaccination efforts in Brazil, where more than 200,000 people have died since the outbreak began - the worst death toll outside the United States.

Brazil's national immunization program currently relies on CoronaVac and the vaccine developed by Oxford University and AstraZeneca Plc - neither of which has received regulatory approval in Brazil.

Anvisa, which has stipulated an efficacy rate of at least 50% for vaccines in the pandemic, has already pressed Butantan for more details of its study, after it filed for emergency use authorization on Friday.

The regulator said it will meet on Sunday to decide on emergency use requests for CoronaVac and the British vaccine.

AstraZeneca failed to deliver active ingredients to Brazil over the weekend, leaving the government scrambling to import finished doses of the vaccine from India to begin inoculations.

↡ Advertisement
  • Shocked 1
  • Haha! 3

Share this post


Link to post
Share on other sites
Hypersonic (edited)

Relax.It's not so easy to make vaccine.

Especially given the traditional inactivated method was always suspected to have some difficulty getting good results against a coronavirus. Case in point, no vaccine was ever developed against SARS and MERS 
Given the Chinese inexperience in running large clinical trials at such short notice (relative to the west), I'm not sure how well the trials were conducted in these developing countries.
Hopefully there can be better data coming out of these countries. 

Even AZN bungled their trial somewhat.

 

 

Edited by Lala81
  • Praise 12

Share this post


Link to post
Share on other sites
Hypersonic

Just send us only two doses lah.

And give both to my MIL.

:grin:

  • Haha! 8

Share this post


Link to post
Share on other sites
Supersonic (edited)
18 minutes ago, Lala81 said:

Relax.It's not so easy to make vaccine.

Especially given the traditional inactivated method was always suspected to have some difficulty getting good results against a coronavirus. Case in point, no vaccine was ever developed against SARS and MERS 
Given the Chinese inexperience in running large clinical trials at such short notice (relative to the west), I'm not sure how well the trials were conducted in these developing countries.
Hopefully there can be better data coming out of these countries. 

Even AZN bungled their trial somewhat.

 

 

why prc do not explore mRNA method for making the vaccine

the method that prc chosen is easier (old proven method) and higher rate to success [confused] 

i read the only advantage of Sinovac is no need special cold storage and easy for transport and distribution

E7E0E2CB-FB45-41D3-A2B5-1817A09D8432.jpeg

Edited by Wt_know
  • Praise 2

Share this post


Link to post
Share on other sites
Supersonic
49 minutes ago, Lala81 said:

Relax.It's not so easy to make vaccine.

Especially given the traditional inactivated method was always suspected to have some difficulty getting good results against a coronavirus. Case in point, no vaccine was ever developed against SARS and MERS 
Given the Chinese inexperience in running large clinical trials at such short notice (relative to the west), I'm not sure how well the trials were conducted in these developing countries.
Hopefully there can be better data coming out of these countries. 

Even AZN bungled their trial somewhat.

 

 

Just curious, does it mean that the older types or traditional vaccine that was pumped into our bodies when we were children, efficacy is only about 50%, based on Sinovac results ? [:p]

Share this post


Link to post
Share on other sites
5th Gear

Not surprising ler….not easy to make vaccines as it takes years ler.

the normal flu vaccine also took 15 or more years to develop and is not 100% efficacy ler, i think is also roughly 50% only. You will still get flu even though you have take the normal flu jab! period!

they have done a good job in coming out with one over this short period of time.

  • Praise 4

Share this post


Link to post
Share on other sites

5th Gear
2 minutes ago, Kb27 said:

Just curious, does it mean that the older types or traditional vaccine that was pumped into our bodies when we were children, efficacy is only about 50%, based on Sinovac results ? [:p]

yes, the normal flu efficacy is roughly 50-60%...what i recall during my pharma days many moons ago...[laugh]

you will still get flu even after the jab...[laugh]

  • Praise 2

Share this post


Link to post
Share on other sites
Hypersonic

Ask you all ah:

When my turns come, will kena which one ah?

  • Haha! 1

Share this post


Link to post
Share on other sites
Moderator

anyone tested the Russian vaccine?

Share this post


Link to post
Share on other sites
Hypersonic
1 minute ago, Jman888 said:

anyone tested the Russian vaccine?

Inject already become like this :grin:

 

F238C448-234B-42FD-B141-67CC1444C58C.jpeg

  • Haha! 5

Share this post


Link to post
Share on other sites
Turbocharged
7 minutes ago, Spidey10 said:

yes, the normal flu efficacy is roughly 50-60%...what i recall during my pharma days many moons ago...[laugh]

you will still get flu even after the jab...[laugh]

It’s because the flu virus is constantly mutating. The vaccine you got, may not guard against the infected flu virus that hits you. 

  • Praise 1

Share this post


Link to post
Share on other sites
Supersonic

There are other choices... this is another commercial decision.

  • Praise 2

Share this post


Link to post
Share on other sites
Hypersonic
2 minutes ago, Mustank said:

Inject already become like this :grin:

 

F238C448-234B-42FD-B141-67CC1444C58C.jpeg

Wow, 刀枪不入..

  • Haha! 3

Share this post


Link to post
Share on other sites
4th Gear (edited)
55 minutes ago, Wt_know said:

why prc do not explore mRNA method for making the vaccine

Incidentally, our very own Duke-NUS vaccine is mRNA based - beginning 2nd stage trials soon.

https://www.straitstimes.com/singapore/health/vaccine-by-spore-scientists-may-be-available-early-next-year

https://www.todayonline.com/singapore/singapore-arcturus-covid-19-vaccine-seeks-100-healthy-adult-volunteers-next-trial-phase

mRNA is a much more modern platform than the old school inactivated virus vaccines. Easier to produce, adapt & scale. Downside: Not a lot of experience.

Edited by CremornePt
  • Praise 5

Share this post


Link to post
Share on other sites
Hypersonic
Just now, CremornePt said:

 [sunny]See Kali our one is 99.9% [sunny]

And must be administered 1 hour after manufacturing. The whole world will buy air ticket come here 

  • Haha! 4

Share this post


Link to post
Share on other sites
4th Gear

Even Australia is considering a pivot to mRNA based vaccines...

Prof Turner added that the government must pivot towards getting more of the Moderna and Pfizer vaccines.
Read more at https://www.todayonline.com/world/australia-state-records-1-covid-19-case-some-doctors-oppose-vaccine-rollout

https://www.todayonline.com/world/australia-state-records-1-covid-19-case-some-doctors-oppose-vaccine-rollout

But in truth, this is a very complex public health issue. In many cases "good enough" may very well be good enough!

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×